Please provide your email address to receive an email when new articles are posted on . Compared with a dual therapy inhaler, a triple therapy inhaler improved inspiratory capacity in those with COPD.

A JAMA study has found that patients with chronic obstructive pulmonary disease (COPD) who received noninvasive ventilation in addition to home oxygen therapy went longer without being readmitted to ...

Oxygen therapy for COPD is a treatment used to increase the oxygen in your lungs and bloodstream. Research suggests that people with chronic obstructive pulmonary disease (COPD) who use oxygen may ...

Please provide your email address to receive an email when new articles are posted on . Two doses of budesonide/glycopyrrolate/formoterol fumarate decreased the risk ...

COPD, or chronic obstructive pulmonary disease, is a leading cause of disability and death in the U.S., according to the American Lung Association. More than 12.5 million people have been diagnosed ...

The maintenance inhalers available for obstructive lung disease are long-acting beta-agonists (LABAs), long-acting muscarinic antagonists (LAMAs), and inhaled corticosteroids (ICSs). We use all three ...

SAN FRANCISCO -- Patients with chronic obstructive pulmonary disease (COPD) who changed treatment from so-called triple therapy to a two-drug product omitting the inhaled corticosteroid (ICS) ...

Triple therapy for COPD, vs ICS/LABA therapy, was independently associated with ischemic heart disease, heart failure, arrhythmia, and atrial fibrillation/flutter. Cardiovascular events in patients ...

Patients with chronic obstructive pulmonary disease (COPD) receiving triple therapy face an increased cardiovascular risk, according to a study published in the International Journal of Chronic ...

BOSTON--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, today unveiled its next generation airway clearance system, The Vest Advanced Pulmonary Experience (APX ...

Treatment with dupilumab reduced the annualized rate of moderate or severe COPD exacerbations by 30% in the BOREAS trial and 34% in the NOTUS trial compared with placebo. The Food and Drug ...